ArticleFrontiers in cellular and infection microbiology2022
Emergence of a
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Carbapenem resistance mediated byMicrobiology spectrum · 2026Article
- Identification and Genomic Analysis of the First Salmonella typhimurium Monophasic Variant 1,4,[5],12:i:- Isolate Harbouring a Chromosomally Integrated blaMicrobial biotechnology · 2026Article
- Genetic and Phenotypic Characterization of aAntibiotics (Basel, Switzerland) · 2026Article
- First report of anMicrobiology spectrum · 2026Article
- Clinical and molecular characterization of NDM-9 and NDM-13 producing multidrug-resistant Escherichia coli strains in China.BMC microbiology · 2026Article
- Genomic and functional characterization of ST11-KL64 hypervirulence-associated carbapenem-resistantFrontiers in microbiology · 2026Article
- Epidemiology, resistance profiles, and molecular characteristics of pediatric salmonella isolates: prevalence of a clonalFrontiers in cellular and infection microbiology · 2026Article
- AMRrounds: What goes around comes back around-recurrent KPC-producingJAC-antimicrobial resistance · 2025Article
- First Report in the Americas ofAntibiotics (Basel, Switzerland) · 2025Article
- Molecular epidemiology of carbapenem-resistantPeerJ · 2025Article
- Emergence of KPC-2 and NDM-13-coproducing carbapenem-resistant hypervirulentFrontiers in microbiology · 2025Article
- Emergence of a clinical Salmonella enterica serovar 1,4,[5], 12: i:-isolate, ST3606, in China with susceptibility decrease to ceftazidime-avibactam carrying a novel blaEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Molecular characterization of IncFII plasmid carryingmSphere · 2023Article
- Complete-genome sequencing and comparative genomic characterization of blaBMC genomics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New Delhi metallo-β-lactamase-13 (NDM-13) is an NDM variant that was first identified in 2015 and has not been detected in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.